Postal Code: 550001;
Contact Tel: 0851-85975027
How many ways to get there First of all, you need to determine your starting point.
The National Bureau of Medical Security of the People's Republic of China*** and the State Council is an organization directly under the State Council. It is at the vice-ministerial level and was established in March 2018. Its main functions are to formulate and organize the implementation of policies, planning and standards for medical insurance, maternity insurance, medical assistance and other medical security systems, supervise and manage the relevant medical security funds, improve the national telemedicine management and expense settlement platform. It also organizes the formulation and adjustment of prices and charges for medicines and medical services, formulates policies on bidding and procurement of medicines and medical consumables and supervises their implementation, and supervises and manages the relevant service behaviors and medical costs of medical institutions included in the scope.
After the establishment of the Medical Insurance Bureau, it will become the most concerned government department for pharmaceutical and medical device companies. There are three reasons for this:
1. Market access
For the domestic pharmaceutical industry, what is market access? We can narrowly understand: bidding, medical insurance. If the drugs can not pass the bidding, they will lose the entire hospital market. And, if the drugs can't enter the medical insurance catalog, even if they pass the bidding, it will have a big impact on their market. Bidding and health insurance catalog are market access, and the importance of these two rights now in the hands of the Health Insurance Bureau cannot be overstated.
2. Strict control of drug use
Medicare cost control is obviously still the key word in 2018. Under the big action of health insurance cost control, for pharmaceutical companies, entering the catalog is only a threshold, hospital access and health insurance contribution standards are the most important. The health insurance bureau has the right to control costs at the source, and previously had direct control over high-dose drugs and ancillary medicines. In addition, under the health insurance payment standard, hospitals will be prompted to use the lowest cost drugs to treat patients on the basis of rational drug use. In the future, under the health insurance environment, the interests of all parties will be more obvious game.
3. Directly determine the price of drugs
Previously, the price of drugs, the National Development and Reform Commission is responsible for pricing, the Ministry of Human Resources and Social Security is responsible for the health insurance catalog, the Commission is responsible for the bidding and procurement. Finally paid by health insurance. Spenders can not talk about the price and standardized use, resulting in increasing pressure on health insurance. Now, the medical insurance bureau to take over the bidding and procurement of drugs, on the one hand, reflects the "who pays the bill, who do the market". On the other hand, in the actual health insurance funds, the winning price of drugs will be closely integrated with the health insurance payment standards, to maximize the benefits of all parties.